-
February 22, 2019Elpiscience Announces Clinical Trial Approval of ES101 in China
Shanghai, February 22, 2019, Elpiscience Biopharma, Ltd. announced today that the bispecific antibody ES101 has been approved by the Center for Drug Evaluation (CDE) for clinical trials in China. ES10...
-
December 03, 2018Elpiscience Announces the Completion of Series A+ Financing of 35 Million USD
Shanghai, 3rd December 2018. Elpiscience announced today that it has completed a 35 million USD series A+ round of financing led by Hillhouse Capital, with participation from CDH Investments...
-
October 20, 2018Elpiscience Announces Filing of IND for ES101
Shanghai, 2018.11.20. Elpiscience announced today that it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation o...
-
May 01, 2018Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-106 (欧洲杯买球网APP) in Greater China
Shanghai and San Diego, May 1st 2018. Elpiscience Biopharmaceutical Ltd (Elpiscience) has entered into a licensing agreement with Inhibrx, Inc., pursuant to which Elpiscience was granted an exclu...
-
March 01, 2018Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-105 (ES101) in Greater China
Shanghai and San Diego, March 01st 2018. Elpiscience Biopharmaceutical, Ltd. (Elpiscience), a biotech company focusing on the discovery and development of next-generation cancer immunotherapies, ...
-
October 08, 2017Elpiscience Announces Inauguration in Zhangjiang
Shanghai, October 8, 2017. Elpiscience, a start-up biopharma focusing on cancer immunotherapies, announces that it officially starts the operation in Zhangjiang High-Tech Park. Elpiscience was fo...
